Get the Stockscreener App
8.82
3.04%
0.26
After Hours:
8.81
-0.010
-0.11%
Immunitybio Inc stock is traded at $8.82, with a volume of 15.41M.
It is up +3.04% in the last 24 hours and up +2.44% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$8.56
Open:
$8.41
24h Volume:
15.41M
Relative Volume:
0.44
Market Cap:
$9.07B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-22.63
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
+12.79%
1M Performance:
+2.44%
6M Performance:
+223.08%
1Y Performance:
+219.57%
1-Day Range:
$8.345
$8.87
1-Week Range:
$8.022
$9.30
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.82 | 8.80B | 113.29M | -351.47M | -309.19M | -0.3898 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
After years of delays, new deadline looms in 2028 for drug manufacturing plant in Dunkirk - Buffalo News
Assessing ImmunityBio (IBRX) Valuation After NCCN ANKTIVA Update And NK Cell Therapy Progress - simplywall.st
ImmunityBio Inc Trade Ideas — SWB:26CA - TradingView
ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer - Insider Monkey
ImmunityBio Stock Jumps on Big Cancer Breakthrough - TipRanks
5 Most Buzzing Stocks to Buy with the Highest Upside Potential - Insider Monkey
ImmunityBio Highlights ANKTIVA Surge, FDA Papillary Filing and Key 2026 Milestones at Conference - MarketBeat
Heights Capital Management Inc. Purchases New Position in ImmunityBio, Inc. $IBRX - MarketBeat
IBRX Stock Rises After NCCN Guideline Update Expands ANKTIVA’s UseRetail Expects Sales To Surge - Stocktwits
Is 28.9% Fall In ImmunityBio (IBRX) Stock A Buying Opportunity? - Trefis
ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion - Seeking Alpha
ImmunityBio Stock To $6? - Trefis
ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use - Benzinga
ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use - Benzinga
NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus - Yahoo Finance
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include AN - PharmiWeb.com
Will Anktiva Remain a Key Factor in ImmunityBio’s Revenue Expansion in 2026? - Bitget
ImmunityBio (NASDAQ:IBRX) Given "Buy" Rating at D. Boral Capital - MarketBeat
Why Is ImmunityBio (IBRX) Stock Jumping Today? ANKTIVA Gains NCCN Backing - Tokenist
Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026? - TradingView
IBRX Stock Is Rising Pre-Market On This Cancer Treatment Expansion - Stocktwits
ImmunityBio gains on NCCN guidelines update (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have been updated to officially include Anktiva (generic name: N-803) in combination with BCG as a treat - Bitget
Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA - Business Wire
IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins - Stocktwits
ImmunityBio (NASDAQ:IBRX) Stock Price Down 2.1%Here's What Happened - MarketBeat
ImmunityBio rises after updates on cell therapy programs - MSN
IBRX Stock Jumps on Progress in NK Cell Therapy Production - Yahoo Finance
Is ImmunityBio, Inc. (IBRX) a good stock to buy now? - MSN
Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now? - Insider Monkey
Earnings call transcript: ImmunityBio’s Q4 2025 EPS beats forecast, stock surges - Investing.com Nigeria
ImmunityBio resubmits bladder cancer application to FDA By Investing.com - Investing.com Nigeria
ImmunityBio (IBRX) climbs 7.3% as firm nears development of 'world bank of NK cells' - MSN
BTIG Research Upgrades ImmunityBio (NASDAQ:IBRX) to "Strong-Buy" - MarketBeat
ImmunityBio (IBRX) Climbs 7.3% as Firm Nears Development of ‘World Bank of NK Cells’ - Insider Monkey
Is It Too Late To Reassess ImmunityBio (IBRX) After Its 315% Year To Date Surge - Yahoo Finance
ImmunityBio’s European Expansion Boosts Market Reach - timothysykes.com
ImmunityBio (NASDAQ:IBRX) Stock Price Up 7.3%Time to Buy? - MarketBeat
IBRX Stock Rises 9%: ImmunityBio Reports Breakthrough In NK Cell Therapy Production - Stocktwits
ImmunityBio’s Market Expansion Amidst Financial Challenges - StocksToTrade
IBRX Stock: Anktiva Receives Approvals and Future Steps Ahead - Bitget
ImmunityBio Stock Jumps After NK-Cell Manufacturing Update Puts Anktiva Expansion Back in Focus - TechStock²
IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking - Yahoo Finance
ImmunityBio Valuation: Paying 33x Sales for Anktiva - TradingView
IBRX Stock: Anktiva's Approvals and What Comes Next - Yahoo Finance
ImmunityBio Expands Reach with European Approval, IBRX Stock Gains Momentum - timothysykes.com
ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell? - sharewise.com
ImmunityBio (NASDAQ:IBRX) Shares Gap UpWhat's Next? - MarketBeat
ImmunityBio Shares Surge 295% Year-to-Date: Should You Buy, Hold, or Sell? - Bitget
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 - PharmiWeb.com
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors - Investing News Network
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):